



BIODIEM LTD
ABN 20 096 845 993
Level 4,
100 Albert Road,
South Melbourne, Victoria, 3205
Australia
Phone: +613 9692 7240
Web: www.biodiem.com

Announcement

Changes to BioDiem Limited Board of Directors

Melbourne, 8 Sep 2021: Australian vaccine technology company BioDiem Ltd (“BioDiem”) today announced changes to its board of directors with the retirement of Professor Arthur Kwok Cheung Li and the appointment of Mr Fergus Mak Po Kan.

Professor Arthur Kwok Cheung Li has been a valuable contributor to the board over many years in particular playing a key role in the negotiation and finalisation of BioDiem’s live attenuated influenza vaccine (LAIV) licence to BioDiem’s Chinese licensee, Changchun BCHO Biotechnology Co. The BioDiem board expresses its gratitude for Professor Li’s generous and significant participation.

Mr Fergus Mak is a professional Financial Analyst. He holds a BSc in Economics from the University of Warwick and an MSc in Project Analysis, Finance & Investment from the University of York. He has been with The Bank of East Asia, Limited for over 30 years, and has served across a number of functional areas including business development, trust, legal, mergers and acquisitions, and capital management.

Mr Hugh Morgan AC, chairman of the BioDiem board said “We are fortunate to have had the skills and experience of Professor Li for so many years and are sorry to see him leave. The Board welcomes Mr Fergus Mak and looks forward to his advice and engagement in the company’s promising development.”

- ENDS -

About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. BioDiem’s business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem’s lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply.

Biodiem has two commercial licencees:

- Changchun BCHO Biotechnology Co (China) launched Defluvac™ in China in August 2020; and
- Serum Institute of India’s Nasovac-S™ is marketed in India.

Further information

Julie Phillips, Chief Executive Officer
BioDiem Ltd
Phone +61 3 9692 7240
Email jphillips@biodiem.com
Twitter @biodiem @opalbiosciences